Chart Industries, Inc. GTLS

Richtech Robotics (RR) will be exhibiting at CES 2025, taking place in Las Vegas on January 7-10, 2025. The Company will be at North Hall, Booth 8549 showcasing its robotics solutions for the hospitality and healthcare industries. On display will be Richtech Robotics’ ADAM and Scorpion AI-powered service solutions, which utilize NVIDIA AI technology to interact with customers, provide personalized recommendations based on mood and preferences, adapt to changes in their environment, and learn and replicate a variety of tasks similar to humans, with high levels of precision and accuracy. In addition, the company will also showcase two of its autonomous delivery robots, Matradee Plus and Medbot. Three demos will be available for those stopping by Richtech Robotics’ booth: Company Intro: ADAM welcomes guests and provides an introduction to Richtech Robotics. Dance Party: ADAM and Scorpion come to life in an entertaining, choreographed dance performance. Gift Demo: Scorpion selects a gift for a customer and hands it to Matradee Plus, which delivers the gift directly to them.

Funny! A company with Financial operation data falsified and embellished through manipulating fake purchase order, looks abnormal to have increasing stock price recent days. In particular, after Q3 report came out with missing market expectations.

About Destiny Tech100

Destiny's flagship offering, the Destiny Tech100, will be a publicly-listed portfolio of 100 of the top venture-backed private technology companies, providing everyday investors access to many of the world's most exciting private businesses.

Current Tech100 holdings include: SpaceX, OpenAI, Epic Games, Discord, Superhuman, and Stripe. For a comprehensive list of holdings, visit the fund website www.destiny.xyz/tech100.

Image for Press Release 1867753

View source version on businesswire.com: https://www.businesswire.com/news/home/20240327776952/en/

$PTC Therapeutics(PTCT.US)$ ?????????????? Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.